Securities · Claims Open

$74M Amgen Securities Settlement (AMGN): Investors Who Bought From July 2020 to April 2022 Can File a Claim

Published November 21, 2026

Investors who bought or otherwise acquired Amgen Inc. (AMGN) common stock between July 29, 2020 and April 27, 2022 may qualify to claim a pro rata share of the $74 million Amgen securities class action settlement. Claims are due February 9, 2027, and trade records are required.

Prescription capsules, representing biotechnology drugmaker Amgen

Current Status

Claims are open, and the claim deadline is February 9, 2027. The court has preliminarily approved the $74 million settlement and set a settlement hearing for March 2, 2027 to decide whether to grant final approval. Final approval has not been granted, and no payment date had been announced as of November 21, 2026.

Status Claims Open
Claim Deadline February 9, 2027
Estimated Payout Pro rata share of $74M Based on recognized loss under the plan of allocation · no per-share figure published here
Proof Required Yes Brokerage statements or confirmations for AMGN trades and holdings

What Changed Recently?

Notice of the settlement went out in November 2026, opening the claim period in In re Amgen Inc. Securities Litigation, No. 1:23-cv-02138, before U.S. District Judge John P. Cronan in the Southern District of New York. The parties filed the proposed $74 million settlement in July 2026.

The case, filed in March 2023, alleges that Amgen waited too long to tell investors that the IRS was seeking about $10.7 billion in back taxes and penalties for tax years 2010 through 2015, a dispute over profits the IRS says Amgen shifted to its manufacturing operation in Puerto Rico. The plaintiffs allege Amgen's share price fell 6.5% on August 4, 2021 and 4.3% on April 28, 2022 after the company disclosed its tax exposure. The court denied Amgen's motion to dismiss in 2024. Amgen has said it believes the claims lack merit, and the settlement includes no admission of liability or wrongdoing. The lead plaintiff is the Asbestos Workers Philadelphia Pension Fund, represented by Robbins Geller Rudman & Dowd LLP.

Who Qualifies?

The settlement class covers persons and entities that purchased or otherwise acquired Amgen common stock during the class period, July 29, 2020 through April 27, 2022. The full class definition, including the persons excluded from the class and anyone who opts out, is set out in the notice on the settlement website.

The underlying IRS dispute is not part of this case. It remains before the U.S. Tax Court, and the class settlement does not resolve it.

How Much Can You Get?

The $74 million cash fund, after court-approved attorneys' fees and expenses and administration costs, is divided among approved claimants under the plan of allocation in the notice. Each claimant's share depends on a recognized-loss calculation that turns on when Amgen shares were bought and sold relative to the dates of the alleged stock drops, and on how many valid claims are filed. No per-share recovery estimate is given on this page; the notice on the settlement website carries the official figures.

What Proof or Notice ID Is Required?

A securities claim is a proof of claim backed by trade records. Claimants list their purchases, acquisitions and sales of Amgen common stock, along with their holdings at the relevant dates, and supply brokerage statements or trade confirmations that document them.

What Is the Deadline?

Claims are due February 9, 2027. The official settlement website could not be reached on November 21, 2026, so the time of day, any time zone, and whether a mailed claim must be postmarked or received by that date were not confirmed; the notice on the settlement website controls. Requests to opt out and objections are also due February 9, 2027.

How Do You Take Action?

Claims are filed through the official Amgen Securities Settlement website, run by claims administrator Verita Global, which posts the notice, the claim form and the plan of allocation.

What Happens Next?

The court will consider final approval, the plan of allocation and class counsel's fee request at the March 2, 2027 settlement hearing. If the settlement is approved, the administrator reviews claims and calculates each recognized loss before distributing the fund. No payment date had been announced as of November 21, 2026.

Sources and Verification

The claim deadline comes from claims administrator Verita Global's settlement case list, which links the case to the official settlement website. Settlement terms, the class period and Amgen's response were reported by Reuters, as republished by Insurance Journal, and Bloomberg Law. The settlement hearing date comes from lead counsel's court-approved summary notice published on Business Wire on November 18, 2026.

Questions

Does the Amgen settlement resolve Amgen's dispute with the IRS?

No. The $74 million settlement resolves shareholders' claims about how and when Amgen disclosed the tax dispute. The underlying dispute with the IRS over tax years 2010 through 2015 is a separate proceeding in the U.S. Tax Court and is not affected by the class settlement.

Is this the same as the earlier $95 million Amgen securities settlement?

No. The $95 million Amgen securities settlement approved in 2016 came from an older case in the Central District of California. The $74 million settlement is in a different case, In re Amgen Inc. Securities Litigation, No. 1:23-cv-02138, in the Southern District of New York, with a 2020–2022 class period.

Does Amgen admit wrongdoing in the settlement?

No. Amgen has said it believes the claims lack merit, and the settlement includes no admission of liability or wrongdoing.

Who is handling Amgen settlement claims?

Verita Global is the claims administrator. Claims, the notice and the plan of allocation are on the official Amgen Securities Settlement website.

For more class actions keep scrolling below.
Settlement Amount $74,000,000
Case Title In re Amgen Inc. Securities Litigation
Case Number 1:23-cv-02138
Court U.S. District Court, Southern District of New York
Final Approval Hearing March 2, 2027 Settlement hearing before Judge John P. Cronan
Administrator Verita Global
Official Website Amgen Securities Settlement

More Open Securities Settlements